Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Belden
BDC
$5.39B
| $16.1M | 0.01% |
293,193
+90,900
| +45% | +$4.86M |
|
1127
Grupo Cibest SA
CIB
$22.6B
| $16.1M | 0.01% |
294,100
-27,300
| -8% | -$1.41M |
|
1128
Amphastar Pharmaceuticals
AMPH
$858M
| $16.1M | 0.01% |
833,000
+102,300
| +14% | +$1.96M |
|
1129
Diageo
DEO
$52.8B
| $16.1M | 0.01% |
95,300
-176,400
| -65% | -$28.7M |
|
1130
Brown-Forman Class A
BF.A
$13B
| $16M | 0.01% |
255,600
+8,500
| +3% | +$522K |
|
1131
Financial Institutions
FISI
$825M
| $16M | 0.01% |
499,700
+31,500
| +7% | +$993K |
|
|
DRRX
1132
DELISTED
DURECT Corp
DRRX
| $16M | 0.01% |
421,921
+20,769
| +5% | +$428K |
|
1133
Village Super Market
VLGEA
$627M
| $16M | 0.01% |
690,900
+38,400
| +6% | +$995K |
|
|
SBNY
1134
DELISTED
Signature Bank
SBNY
| $16M | 0.01% |
117,082
-114,792
| -50% | -$14.4M |
|
1135
lululemon athletica
LULU
$13.6B
| $16M | 0.01% |
69,000
-570,400
| -89% | -$122M |
|
|
SLCA
1136
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $16M | 0.01% |
2,596,812
+852,800
| +49% | +$5.15M |
|
1137
Federal Realty Investment Trust
FRT
$10.2B
| $15.9M | 0.01% |
123,900
-38,166
| -24% | -$5.07M |
|
|
CYOU
1138
DELISTED
Changyou.com Limited American Depositary Share
CYOU
| $15.9M | 0.01% |
1,623,415
+389,292
| +32% | +$3.74M |
|
1139
NACCO Industries
NC
$317M
| $15.9M | 0.01% |
339,044
+26,500
| +8% | +$1.41M |
|
1140
Broadridge
BR
$19.3B
| $15.9M | 0.01% |
128,500
-90,900
| -41% | -$11.1M |
|
1141
Keurig Dr Pepper
KDP
$42.3B
| $15.9M | 0.01% |
547,805
-293,180
| -35% | -$8.42M |
|
|
AKRX
1142
DELISTED
Akorn Inc
AKRX
| $15.9M | 0.01% |
10,570,408
+1,116,539
| +12% | +$4.21M |
|
1143
UMB Financial
UMBF
$11.4B
| $15.8M | 0.01% |
230,800
+34,000
| +17% | +$2.26M |
|
1144
Silgan Holdings
SLGN
$4.3B
| $15.8M | 0.01% |
506,745
-593,935
| -54% | -$18.2M |
|
1145
Manchester United
MANU
$3.94B
| $15.7M | 0.01% |
789,500
+114,600
| +17% | +$1.98M |
|
1146
Robert Half
RHI
$4.25B
| $15.7M | 0.01% |
248,800
-214,500
| -46% | -$12.5M |
|
1147
Stoneridge
SRI
$197M
| $15.7M | 0.01% |
534,919
+4,000
| +0.8% | +$123K |
|
1148
Mattel
MAT
$4.19B
| $15.7M | 0.01% |
+1,156,100
| New | +$13.7M |
|
1149
iShares MSCI Emerging Markets ETF
EEM
$30.5B
| $15.7M | 0.01% |
348,900
-295,000
| -46% | -$12.7M |
|
|
DSPG
1150
DELISTED
DSP Group Inc
DSPG
| $15.6M | 0.01% |
991,800
-85,894
| -8% | -$1.27M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.